Dose interruptions may affect EGFR inhibitor outcomes more than reductions

An exploratory analysis of patient-level data from trials supporting FDA approvals of four EGFR tyrosine kinase inhibitors examined dose modifications in EGFR-mutated non-small cell lung cancer. Interruptions—particularly those lasting at least four consecutive days—were more often associated with progression or death than dose reductions, although effects varied by drug.

Four FDA-approved EGFR inhibitors were evaluated.
Interruptions were more often linked to progression or death than reductions.
Associations varied by drug; no effect estimates are provided.
Further research is needed across therapies and cancer types.

Researchers analyzed patient-level data from clinical trials supporting the original US FDA approvals of afatinib, dacomitinib, mobocertinib and osimertinib for EGFR-mutated non-small cell lung cancer. They assessed daily dose received, interruptions and reductions, and their associations with progression-free survival (PFS) and overall survival (OS). The exploratory analysis used time-dependent Cox models for daily dose received and landmark models at 30, 60 and 90 days for early interruptions and reductions.

Across the four drugs, the association between dose modifications and risk of death varied. Dose interruptions, including interruptions of four or more consecutive days, were more often associated with a higher risk of progression or death than dose reductions. The abstract provides no effect estimates or sample sizes.

The findings suggest that reductions may have less impact on efficacy than missed or interrupted treatment, but they do not establish causality or support a universal dose-management approach. The analysis was limited to selected drugs used as monotherapy in this population; the authors call for further study of other EGFR therapies, drug classes and cancer types.

In practice

For patients with EGFR-mutated non-small cell lung cancer receiving afatinib, dacomitinib, mobocertinib or osimertinib monotherapy, this exploratory analysis found that dose interruptions were more often associated with progression or death than dose reductions. It does not show that interruptions cause poorer outcomes, and the abstract provides no effect estimates or sample sizes. Associations varied by drug, and the findings do not establish a preferred dose-modification strategy or apply automatically to other EGFR therapies or cancers.

AI-generated clinical interpretation · Not editor-reviewed

AI summary · Not yet editor-reviewed

Is this summary clinically accurate?

Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.

Source

Clinical Cancer Research: Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations ↗

This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.